Matches in Nanopublications for { ?s ?p "[JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_assertion description "[JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_provenance.
- NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_assertion description "[JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.